AU2020351782A1 - Pyridone compounds and methods of use in the modulation of a protein kinase - Google Patents

Pyridone compounds and methods of use in the modulation of a protein kinase Download PDF

Info

Publication number
AU2020351782A1
AU2020351782A1 AU2020351782A AU2020351782A AU2020351782A1 AU 2020351782 A1 AU2020351782 A1 AU 2020351782A1 AU 2020351782 A AU2020351782 A AU 2020351782A AU 2020351782 A AU2020351782 A AU 2020351782A AU 2020351782 A1 AU2020351782 A1 AU 2020351782A1
Authority
AU
Australia
Prior art keywords
alkyl
alkylene
membered
cycloalkyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020351782A
Other languages
English (en)
Inventor
Lynne BANNEN
Minna Bui
Faming Jiang
Jack Maung
Andrew RAUB
Justin SALVANT
Benjamin Spangler
Kin Tso
Yong Wang
Wei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2020351782A1 publication Critical patent/AU2020351782A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020351782A 2019-09-26 2020-09-25 Pyridone compounds and methods of use in the modulation of a protein kinase Abandoned AU2020351782A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906647P 2019-09-26 2019-09-26
US62/906,647 2019-09-26
US202063053530P 2020-07-17 2020-07-17
US63/053,530 2020-07-17
PCT/US2020/052850 WO2021062245A1 (en) 2019-09-26 2020-09-25 Pyridone compounds and methods of use in the modulation of a protein kinase

Publications (1)

Publication Number Publication Date
AU2020351782A1 true AU2020351782A1 (en) 2022-04-21

Family

ID=72827019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020351782A Abandoned AU2020351782A1 (en) 2019-09-26 2020-09-25 Pyridone compounds and methods of use in the modulation of a protein kinase

Country Status (8)

Country Link
US (1) US12371428B2 (https=)
EP (1) EP4034532A1 (https=)
JP (1) JP2022551422A (https=)
CN (1) CN114787144A (https=)
AU (1) AU2020351782A1 (https=)
CA (1) CA3155924A1 (https=)
TW (1) TW202126651A (https=)
WO (1) WO2021062245A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
CA3211063A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
WO2023114809A1 (en) 2021-12-16 2023-06-22 Kinnate Biopharma Inc. Inhibitors of met kinase
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN121038792A (zh) * 2023-04-17 2025-11-28 赛琳治疗公司 用met激酶抑制剂治疗癌症
WO2024217587A1 (zh) * 2023-04-21 2024-10-24 南京正大天晴制药有限公司 具有axl抑制活性的取代吡嗪化合物
WO2024259060A1 (en) * 2023-06-16 2024-12-19 Kinnate Biopharma Inc. Inhibitors of met kinase
CN117343046A (zh) * 2023-09-25 2024-01-05 辽宁大学 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
WO2025096463A1 (en) * 2023-10-30 2025-05-08 Vibliome Therapeutics, Llc Plk4 modulators
CN118878515B (zh) * 2024-06-19 2025-10-28 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
JP2009537632A (ja) * 2006-05-19 2009-10-29 バイエル・ヘルスケア・アクチェンゲゼルシャフト 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013180949A1 (en) 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
CN104072480B (zh) 2013-03-27 2016-12-28 沈阳药科大学 喹啉类化合物及其制备方法和应用
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
ES2749726T3 (es) 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
CN108530426A (zh) 2017-03-02 2018-09-14 沈阳药科大学 含喹喔啉酮的4-苯氧基取代喹啉类化合物及其应用
WO2019080723A1 (zh) 2017-10-26 2019-05-02 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN109896997A (zh) 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
US20210177828A1 (en) 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
ES2985569T3 (es) 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
CA3114987A1 (en) 2018-08-27 2020-03-05 Beijing Yuezhikangtai Biomedicines Co., Ltd. Multi-substituted pyridone derivatives and medical use thereof
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
JP7542613B2 (ja) * 2019-09-06 2024-08-30 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ Ａｘｌとｃ－Ｍｅｔキナーゼ阻害活性を有する化合物およびその製造と使用
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
JP2023514725A (ja) 2020-02-24 2023-04-07 エグゼリクシス， インコーポレイテッド 化合物および使用方法

Also Published As

Publication number Publication date
US12371428B2 (en) 2025-07-29
EP4034532A1 (en) 2022-08-03
CN114787144A (zh) 2022-07-22
US20220315579A1 (en) 2022-10-06
CA3155924A1 (en) 2021-04-01
WO2021062245A1 (en) 2021-04-01
TW202126651A (zh) 2021-07-16
JP2022551422A (ja) 2022-12-09

Similar Documents

Publication Publication Date Title
US12371428B2 (en) Pyridone compounds and methods of use
EP3204360B1 (en) Therapeutic compounds and uses thereof
CN107207493B (zh) 作为布罗莫结构域抑制剂的经取代的吡咯并吡啶
EP4294804B1 (en) Pyridone compounds and methods of use
TW202400609A (zh) 三環吡啶酮及嘧啶酮
US20170333406A1 (en) Therapeutic compounds and uses thereof
WO2021173591A1 (en) Compounds and methods of use
JP2025517733A (ja) ヘテロアレーン、それを含む医薬組成物、及びその使用方法
TW202340212A (zh) 治療性化合物及其使用方法
WO2022020716A1 (en) Heterocyclic inhibitors of tead for treating cancer
CN117440951A (zh) 吡啶酮化合物和使用方法
US20260035364A1 (en) Bicyclic tetrahydrothiazepine derivatives
HK40079390A (en) Substituted pyrrolopyrdines as inhibitors of bromodomain
US20250236617A1 (en) Bicyclic tetrahydrothiazepine derivatives
HK1248695B (zh) 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物
HK1243073B (zh) 治療性化合物及其用途
HK1242696B (zh) 治療性化合物及其用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application